摘要
目的:研究左卡尼汀与表柔比星(EPI)联合应用对肺腺癌GLC-82细胞增殖及细胞凋亡的影响。方法:MTT比色法检测肺腺癌GLC-82细胞增殖的变化情况。流式细胞仪检测GLC-82细胞周期和凋亡情况。蛋白质印迹法检测Bcl-2、Bcl-xl和Bax蛋白的表达。结果:与空白对照组比,单给药左卡尼汀(20μg/mL)24h后,细胞的促进生长率为37.56%,F=46.287,P=0.001;48h后为33.33%,F=41.638,P=0.001。EPI联合不同浓度的左卡尼汀后,减弱了EPI对GLC-82细胞生长的抑制作用,联合给药24和48h后,对GLC-82细胞毒作用的减弱较明显,减少率分别为12.14%(F=20.527,P=0.002)和18.52%(F=27.269,P=0.001),差异有统计学意义。左卡尼汀上调Bcl-2和Bcl-xl的蛋白表达,Bax蛋白表达无明显变化;联合给药后Bcl-2和Bcl-xl的蛋白表达明显增加。结论:左卡尼汀与EPI联合应用对肺腺癌GLC-82细胞的增殖有一定影响,其作用机制可能使G0/G1期细胞比例增加,促进细胞的有些分裂,并通过上调Bcl-2和Bck-xl蛋白的表达减弱EPI的诱导凋亡作用。
OBJECTIVE： To investigate the proliferation and cell apoptosis effects of combination treatment with L-earnitine and EPI on lung adenocarcinoma GLC-82 cell. METHODS： The cell proliferation was examined by MTT as- say. Cell cycle and cell apoptosis were analyzed by flow cytometry. The expression of Bcl-2 ,Bcl-xl and Bax proteins were measured by Western blot. RESULTS： After 24 h and 48 h, the proliferation rate of L-carnitine （20 μg/mL） were 37.56% （F=46.287,P=0.001） and 33.33% （F=41.638,P=0.001）,respectively. Cells were treated withL-carnitine and EPI,whieh reduced the inhibitory effects on GLC 82 cell. After 24 h and 48 h, the antagonized rate of combination treatment were 12.14% （F=20.527,P=0.002） and 18.52% （F=27.269,P=0.001）,respectively. The difference was significant. The expression of Bcl 2 and Bcl-xl proteins was up-regulated by L-carnitine. The expression of Bax protein was no difference. The expression of Bcl 2 and Bcl-xl proteins were significantly increased by combination treatment with L-carnitine and EPI. CONCLUSIONS：Combination treatment with L-carnitine and EPI can weaken the cytotoxicity of EPI on GLC-82 cells. After treated with L-carnitine,the proportion of G0/Gl phase is significantly increased,S-phase cells is reduced,the phenomenon of induced early apoptosis is disappeared and cell apoptosis is significantly decreased by upregu- lating the expression of Bcl-2 and Bcl-xl.
出处
《中华肿瘤防治杂志》
CAS
北大核心
2013年第10期744-748,共5页
Chinese Journal of Cancer Prevention and Treatment
基金
天津市卫生局科技基金(2010KZ75)
天津医科大学附属肿瘤医院科研基金(1031)
